Cargando…
The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials
Background: Stable angina is a common condition with high morbidity and mortality rates. It has been reported that combining oral Chinese patent medicines (OCPMs) and Western medicine (WM) could potentially achieve a better effect than WM alone. However, the optimal OCPMs for stable angina remain co...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428755/ https://www.ncbi.nlm.nih.gov/pubmed/36059992 http://dx.doi.org/10.3389/fphar.2022.918689 |
_version_ | 1784779192800378880 |
---|---|
author | Huang, Peiying Li, Zhishang Chen, Li Zeng, Jing Zhao, Shuai Tang, Yong Huang, Bixuan Guan, Hansu Chen, Yan Feng, Yuchao Lei, Sisi Wu, Qihua Zhang, Haobo Huang, Xiaoyan Zeng, Linsheng Liu, Yuxiang Zeng, Zhongyi Chen, Bojun |
author_facet | Huang, Peiying Li, Zhishang Chen, Li Zeng, Jing Zhao, Shuai Tang, Yong Huang, Bixuan Guan, Hansu Chen, Yan Feng, Yuchao Lei, Sisi Wu, Qihua Zhang, Haobo Huang, Xiaoyan Zeng, Linsheng Liu, Yuxiang Zeng, Zhongyi Chen, Bojun |
author_sort | Huang, Peiying |
collection | PubMed |
description | Background: Stable angina is a common condition with high morbidity and mortality rates. It has been reported that combining oral Chinese patent medicines (OCPMs) and Western medicine (WM) could potentially achieve a better effect than WM alone. However, the optimal OCPMs for stable angina remain controversial and merit further empirical research. Methods: PubMed, Embase, Web of Science, Cochrane Library, Ovid-Medline, Clinical Trials.gov, China National Knowledge Infrastructure, Wanfang Database, Weipu Journal Database, and Chinese Biomedical Literature Database were all searched from inception to 13 March 2022. We employed Version 2 of the Cochrane risk-of-bias tool (ROB2) to assess the overall quality of the selected studies. We also used R 4.1.2 and STATA 14.0 software applications to perform network meta-analysis, followed by sensitivity and subgroup analysis. Results: A total of 179 randomized controlled trials with 16,789 patients were included. The selected trials were all assessed as some concerns. OCPMs combined with WM had a better treatment effect than WM alone. In terms of the effective clinical rate, a significant increase was detected for Qishen Yiqi dripping pill (QSYQ)+WM as compared with Shensong Yangxin capsule (SSYX)+WM, Shexiang Baoxin pill (SXBX)+WM, Tongxinluo capsule (TXL)+WM, Xuefu Zhuyu capsule (XFZY)+WM, Qiliqiangxin capsule (QLQX)+WM, Naoxintong capsule (NXT)+WM, Fufang Danshen dripping pill (FFDS)+WM, and Danlou tablet (DL)+WM. QSYQ + WM had the highest-ranking probability (98.12%). Regarding the effective rate in ECG, QSYQ + WM was superior to SXBX + WM, TXL + WM, DL + WM, FFDS + WM, and NXT + WM. QSYQ + WM ranked first (94.21%). In terms of weekly frequency of angina, QLQX + WM obtained a better effect than FFDS + WM, Kuanxiong aerosol (KXQW)+WM, NXT + WM, QLQX + WM, SSYX + WM, SXBX + WM, and TXL + WM. QLQX + WM ranked first (100.00%). Regarding the duration of an angina attack, KXQW + WM was superior to SSYX + WM; KXQW + WM ranked first (95.71%). Adverting to weekly nitroglycerin usage, TXL + WM had the highest-ranking probability (82.12%). Referring to cardiovascular event rate, DL + WM had the highest effect (73.94%). Additionally, SSYX + WM had the lowest rate of adverse drug reactions (1.14%). Conclusion: OCPMs combined with WM had a higher efficacy. QSYQ + WM, QLQX + WM, KXQW + WM, TXL + WM, DL + WM, SSYX + WM, and SXBX + WM merit further investigation. SXBX + WM is presumably the optimal treatment prescription for both clinically effective and cardiovascular event rates. Further high-quality empirical research is needed to confirm the current results. Systematic Review Registration: URL = https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=316534, CRD 42022316534 |
format | Online Article Text |
id | pubmed-9428755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94287552022-09-01 The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials Huang, Peiying Li, Zhishang Chen, Li Zeng, Jing Zhao, Shuai Tang, Yong Huang, Bixuan Guan, Hansu Chen, Yan Feng, Yuchao Lei, Sisi Wu, Qihua Zhang, Haobo Huang, Xiaoyan Zeng, Linsheng Liu, Yuxiang Zeng, Zhongyi Chen, Bojun Front Pharmacol Pharmacology Background: Stable angina is a common condition with high morbidity and mortality rates. It has been reported that combining oral Chinese patent medicines (OCPMs) and Western medicine (WM) could potentially achieve a better effect than WM alone. However, the optimal OCPMs for stable angina remain controversial and merit further empirical research. Methods: PubMed, Embase, Web of Science, Cochrane Library, Ovid-Medline, Clinical Trials.gov, China National Knowledge Infrastructure, Wanfang Database, Weipu Journal Database, and Chinese Biomedical Literature Database were all searched from inception to 13 March 2022. We employed Version 2 of the Cochrane risk-of-bias tool (ROB2) to assess the overall quality of the selected studies. We also used R 4.1.2 and STATA 14.0 software applications to perform network meta-analysis, followed by sensitivity and subgroup analysis. Results: A total of 179 randomized controlled trials with 16,789 patients were included. The selected trials were all assessed as some concerns. OCPMs combined with WM had a better treatment effect than WM alone. In terms of the effective clinical rate, a significant increase was detected for Qishen Yiqi dripping pill (QSYQ)+WM as compared with Shensong Yangxin capsule (SSYX)+WM, Shexiang Baoxin pill (SXBX)+WM, Tongxinluo capsule (TXL)+WM, Xuefu Zhuyu capsule (XFZY)+WM, Qiliqiangxin capsule (QLQX)+WM, Naoxintong capsule (NXT)+WM, Fufang Danshen dripping pill (FFDS)+WM, and Danlou tablet (DL)+WM. QSYQ + WM had the highest-ranking probability (98.12%). Regarding the effective rate in ECG, QSYQ + WM was superior to SXBX + WM, TXL + WM, DL + WM, FFDS + WM, and NXT + WM. QSYQ + WM ranked first (94.21%). In terms of weekly frequency of angina, QLQX + WM obtained a better effect than FFDS + WM, Kuanxiong aerosol (KXQW)+WM, NXT + WM, QLQX + WM, SSYX + WM, SXBX + WM, and TXL + WM. QLQX + WM ranked first (100.00%). Regarding the duration of an angina attack, KXQW + WM was superior to SSYX + WM; KXQW + WM ranked first (95.71%). Adverting to weekly nitroglycerin usage, TXL + WM had the highest-ranking probability (82.12%). Referring to cardiovascular event rate, DL + WM had the highest effect (73.94%). Additionally, SSYX + WM had the lowest rate of adverse drug reactions (1.14%). Conclusion: OCPMs combined with WM had a higher efficacy. QSYQ + WM, QLQX + WM, KXQW + WM, TXL + WM, DL + WM, SSYX + WM, and SXBX + WM merit further investigation. SXBX + WM is presumably the optimal treatment prescription for both clinically effective and cardiovascular event rates. Further high-quality empirical research is needed to confirm the current results. Systematic Review Registration: URL = https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=316534, CRD 42022316534 Frontiers Media S.A. 2022-08-17 /pmc/articles/PMC9428755/ /pubmed/36059992 http://dx.doi.org/10.3389/fphar.2022.918689 Text en Copyright © 2022 Huang, Li, Chen, Zeng, Zhao, Tang, Huang, Guan, Chen, Feng, Lei, Wu, Zhang, Huang, Zeng, Liu, Zeng and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Huang, Peiying Li, Zhishang Chen, Li Zeng, Jing Zhao, Shuai Tang, Yong Huang, Bixuan Guan, Hansu Chen, Yan Feng, Yuchao Lei, Sisi Wu, Qihua Zhang, Haobo Huang, Xiaoyan Zeng, Linsheng Liu, Yuxiang Zeng, Zhongyi Chen, Bojun The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials |
title | The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials |
title_full | The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials |
title_fullStr | The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials |
title_full_unstemmed | The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials |
title_short | The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials |
title_sort | comparative effects of oral chinese patent medicines combined with western medicine in stable angina: a systematic review and network meta-analysis of 179 trials |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428755/ https://www.ncbi.nlm.nih.gov/pubmed/36059992 http://dx.doi.org/10.3389/fphar.2022.918689 |
work_keys_str_mv | AT huangpeiying thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT lizhishang thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT chenli thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT zengjing thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT zhaoshuai thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT tangyong thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT huangbixuan thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT guanhansu thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT chenyan thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT fengyuchao thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT leisisi thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT wuqihua thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT zhanghaobo thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT huangxiaoyan thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT zenglinsheng thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT liuyuxiang thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT zengzhongyi thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT chenbojun thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT huangpeiying comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT lizhishang comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT chenli comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT zengjing comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT zhaoshuai comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT tangyong comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT huangbixuan comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT guanhansu comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT chenyan comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT fengyuchao comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT leisisi comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT wuqihua comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT zhanghaobo comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT huangxiaoyan comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT zenglinsheng comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT liuyuxiang comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT zengzhongyi comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials AT chenbojun comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials |